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ABSTRACT
Objective: Patients with recurrent epithelial ovarian cancer (EOC) have limited 
treatment options.  Studies have reported that biomarker profiling may help predict 
patient response to available treatments. This study sought to determine the value 
of biomarker profiling in recurrent EOC. 
Results: Patients in the Matched cohort had a median OS of 36 months compared 
to 27 months for patients in the Unmatched cohort (HR 0.62, 95% CI 0.41-0.96; p 
< 0.03). Individual biomarkers were analyzed, with TUBB3, and PGP prognostic for 
survival. Biomarker analysis also identified a molecular subtype (positive for at least 
two of the following markers: ERCC1, RRM1, TUBB3, PGP) with particularly poor 
overall survival. 
Methods: 224 patients from a commercial registry (NCT02678754) with stage 
IIIC/IV EOC at diagnosis, or restaged to IIIC/IV EOC at the time of molecular 
profiling, were retrospectively divided into two cohorts based on whether or not the 
drugs they received matched their profile recommendations. The Matched cohort 
received no drugs predicted to be lack-of-benefit while the Unmatched cohort received 
at least one drug predicted to be lack-of-benefit. Profile biomarker/drug associations 
were based on multiple test platforms including immunohistochemistry, fluorescent 
in situ hybridization and DNA sequencing.
Conclusions: This report demonstrates the ability of multi-platform molecular 
profiling to identify EOC patients at risk of inferior survival. It also suggests a potential 
beneficial role of avoidance of lack-of-benefit therapies which, when administered, 
resulted in decreased survival relative to patients who received only therapies 
predicted to be of benefit. 
INTRODUCTION
Almost a quarter of a million women worldwide 
are diagnosed each year with epithelial ovarian cancer 
(EOC; including primary peritoneal and fallopian tube 
carcinomas) and it is the leading cause of gynecologic 
cancer-related death in developed countries. The 5-year 
survival of EOC patients is only 44% due to the fact 
that 75% of women present with advanced disease [1]. 
Approximately 80% of advanced stage patients who 
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have residual disease after surgery and receive front-line 
platinum-based combination chemotherapy respond and 
experience a median progression free survival (PFS) of 
18 months [2]. Patients who have recurrence of disease 
within 6 months of completion of their initial treatments 
have been traditionally classified as platinum-resistant. 
Fewer than 15% of these patients typically respond to 
the next line of treatment and have a median survival of 
less than a year [3]. Most cases that are initially platinum-
sensitive eventually develop platinum resistance.
There are a variety of EOC histologies with 
distinct molecular profiles and clinical courses [1, 4]. 
For example, high-grade serous ovarian cancer (HGSC) 
accounts for the majority of cases and a disproportionate 
number of deaths. Other subtypes, such as clear cell or 
mucinous ovarian carcinomas, are less common and have 
poor responses to standard therapies used to treat HGSC. 
Additionally, large-scale gene expression analyses have 
identified molecular subtypes within HGSC with variable 
survival rates [5] and degrees of platinum resistance [6].
These variations in treatment response underscore 
the need for molecular characterization of EOC in order 
to identify treatment options that are most likely to 
benefit individual patients. Some published evidence 
supports the use of DNA repair proteins (ERCC1, 
BRCA1/2) as markers for platinum response; however, 
there are conflicting data [5-7]. RRM1, TUBB3/PGP and 
TOP2A have been shown to be predictive of response to 
gemcitabine, taxanes and anthracyclines, respectively, 
and represent drugs commonly used to treat patients with 
EOC [8-12]. Beyond TP53 and BRCA, few mutations 
commonly exist in EOC [13]; however, broad sequencing 
has the potential to identify rare mutations associated with 
potentially effective therapies not typically considered in 
this disease. 
Studies have shown that multiplatform molecular 
profiling (profiling considering both protein and DNA 
abnormalities) has clinical utility in a variety of cancer 
types. A recent study in patients with refractory breast 
cancer showed that tumor profiling resulted in a revision 
of the original treatment decision for every patient, and 
tumor profiling-based therapy resulted in clinical benefit 
for 52% of the 25 heavily pretreated patients [14]. A 
multi-lineage pilot study showed that comprehensive 
molecular profiling identified molecular targets in 
patients with refractory metastatic cancer of multiple 
histogenetic types [15]. In this study, 18 of 66 patients 
treated with a molecularly guided therapy had a longer 
PFS as compared to their prior PFS interval with treatment 
chosen without molecular guidance. Subsequent studies 
have demonstrated the benefit of multiplatform profiling in 
other clinical settings in other tumor types as well [16, 17]. 
Thus, the evidence suggests that multi-platform 
tumor profiling has the potential to assist in clinical 
decision-making and increase the likelihood of response to 
chemotherapy in patients with recurrent EOC. To evaluate 
the effectiveness of one such profile, we evaluated 
clinical data from the Caris observational Registry, 
whereby patient molecular profiling data were collected 
and coupled with clinical outcomes recorded in a central 
database.  The impact of profiling on drug usage, median 
survival and overall survival (OS) was assessed. The 
contribution of individual biomarkers was also measured. 
RESULTS
Patient characteristics
There were 241 EOC patients with advanced stage 
cancers who underwent treatment and had at least 9 
months of follow-up data, diagnostic staging of at least 
IIIC or having metastasis or treatments prior to profiling. 
Of 241 eligible patients, 17 were excluded because they 
received no drugs after the time of tissue collection or the 
drugs they received were not classified by the molecular 
profile (received no drugs of predicted benefit or lack-of-
benefit; Figure 1). 
The analysis population of 224 patients was divided 
into two cohorts based on the matching of treatments to 
profile recommendations. Dividing the group into only 
two cohorts provided a straightforward approach to 
answer the key question: Do patients whose treatments 
consistently follow profile results do better than patients 
whose treatments are inconsistent with profile results? 
Grouping into only two cohorts also allowed for statistical 
power to make significant claims regarding observed 
differences. 
The Matched cohort (n=121) includes patients who 
received at least one treatment associated with potential 
benefit and no treatments associated with lack-of-benefit 
at any time following the date of sample collection for 
the specimen submitted for profiling. The Unmatched 
cohort (n=103) includes patients who received at least one 
treatment associated with potential lack-of-benefit at any 
time following the sample collection date.
Only drugs administered after the date of collection 
of the profiled specimen were used to sort the patients into 
the two cohorts. This method sorted 6 patients into the 
Matched group who received lack-of-benefit therapies 
prior to the profiled sample collection date (patients with 
red and/or yellow treatment boxes in Figure 2A). Sorting of 
these patients into the Matched group did not significantly 
impact the study results. Physician consultations were not 
a part of this study, so no information could be provided 
regarding why patients were or were not treated according 
to profile recommendations.
Patient characteristics (age, race, biopsy site, 
stage at diagnosis and histology) across Matched and 
Unmatched cohorts are shown in Table 1. The Matched 
cohort differed substantially in two categories: stage IC 
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Table 1: Demographics of Matched and Unmatched cohorts
Characteristic Matched n = 121 (%)  Unmatched n = 103 (%)
Age
   <40 2 (1.7) 2 (1.9)
   40-49 19 (15.7) 17 (16.5)
   50-59 33 (27.3) 31 (30.1)
   60-69 37 (30.6) 31 (30.1)
   70-100 30 (24.8) 22 (21.4)
Race
   White 110 (90.9) 91 (88.3)
   Black 3 (2.5) 8 (7.8)
   Asian 6 (5.0) 3 (2.9)
   Other/Unknown 2 (1.7) 1 (1.0)
Primary Site
   Ovary 103 (85.1) 86 (83.5)
   Fallopian tube 9 (7.4) 5 (4.9)
   Peritoneum 9 (7.4) 12 (11.7)
Stage at Diagnosis
I-IA 3 (2.5) 3 (2.9)
IC 10 (8.3) 3 (2.9)
IIA 2 (1.6) 2 (1.9)
IIB 3 (2.5) 3 (2.9)
IIC 1 (0.8) 1 (1.0)
III-IIIA 2 (1.6) 5 (4.9)
IIIB 3 (2.5) 3 (2.9)
IIIC 78 (64.5) 72 (69.9)
IV 13 (10.7) 9 (8.7)
Unknown 6 (5.0) 2 (1.9)
Histology
   Serous 91 (75.2) 85 (82.5)
   Endometrioid 9 (7.4) 3 (2.9)
   Mixed Cell 3 (2.5) 6 (5.8)
   Clear Cell 3 (2.5) 5 (4.9)
   Mucinous 1 (0.8) 2 (1.9)
   Transitional Cell 2 (1.7) 0 (0.0)
   Small Cell 0 (0.0) 1 (1.0)
   Carcinoma,NOS/Adenocarcinoma 12 (9.9) 1 (1.0)
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at diagnosis (8.3% vs. 2.9%) and not-otherwise-specified 
(NOS) histology (9.9% vs. 1.0%). The stage IC Matched 
cohort median survival was lower than the survival for 
the IC Unmatched cohort, indicating that the Matched IC 
group was not contributing bias towards longer survival. 
Resistant histologies (clear cell, small cell and mucinous) 
were more common in the Unmatched cohort, however, 
the survival distribution of these cases did not significantly 
bias OS.
Treatment analysis
Waterfall plots were constructed for both study 
cohorts in order to visualize individual patient monitoring 
times, treatment durations, and post-profiling survival 
(Figure 2). Patients are stratified from left to right by post-
profiling survival time. Green bars indicate drugs received 
predicted to be of benefit while red bars indicate drugs 
predicted to be of lack-of-benefit. Yellow bars indicate 
times where the patient received drugs predicted to be of 
both benefit and lack-of-benefit at the same time. In the 
Matched cohort, 31% of patients are deceased vs. 46% 
of the Unmatched cohort patients. The median follow-up 
time for the Matched cohort was 475 days vs. 372 days for 
the Unmatched cohort.
The most frequently administered chemotherapy 
agents with their associated biomarker frequency 
distribution are presented in Table 1. Patients in the 
Matched cohort received a median of 3.88 lines of 
therapy vs. 5.02 lines for patients in the Unmatched 
cohort (calculated as therapies administered after 
diagnosis; Figure 3). 83% of patients in the Unmatched 
cohort received at least one drug predicted to be of 
benefit, while 56% received two or more benefit 
drugs. This highlights the fact that the most significant 
distinguishing factor between the two cohorts is the 
difference in administration of lack-of-benefit drugs, not 
benefit drugs. Several administered drugs did not have a 
recommendation for or against and appear in the “neither” 
category. This “neither” category makes up 27% of 
drugs administered in the Matched cohort vs. 30% in the 
Unmatched cohort. Two common agents in the “neither” 
category were bevacizumab (given to 34% patients) and 
cyclophosphamide (given to 5% of patients). These drugs 
are not included in Table 2 as the molecular profiling panel 
studied in this report does not associate a biomarker with 
either drug.
Figure 1: Retrospective analytic schema.
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Figure 2: Plots showing duration of monitoring, duration of treatments received before and after profiling, and post-
profiling survival for each patient in the study.  Each column along the x-axis represents one patient. The y-axis is time (days). The 
zero point of the y-axis is the time of profiling. Patients are sorted left to right based upon survival time post-profiling.  Grey bars represent 
the total time monitored, from diagnosis to either death or last follow-up. Black bars at the top of a column represent death. The colored 
bars represent drug treatments and are coded relative to their match status with the patient’s molecular profile. Green bars represent time 
on a therapy associated with benefit. Red bars represent time on a therapy associated with lack-of-benefit. Yellow bars represent time on a 
combination regimen associated with both benefit and lack-of-benefit. Blue bars represent time on a therapy associated with neither benefit 
nor lack-of-benefit. Panel A shows patients in the Matched cohort, and Panel B shows patients in the Unmatched cohort. 
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Table 2 also reports the frequency of administration 
of drugs that were predicted to be of benefit or lack-of-
benefit for the cohorts. As expected, drugs most commonly 
used to treat EOC were administered at similar rates 
whether or not they were predicted to be of benefit to the 
patient (platinum agents and taxanes): 94% and 85% of 
patients who were predicted not to benefit from platinum 
and taxanes, respectively, received the agents anyway. On 
the other hand, gemcitabine and doxorubicin were less 
likely to be administered to patients who were predicted 
to not benefit from these drugs (only 20% and 22% 
received gemcitabine or doxorubicin with a lack-of-benefit 
prediction). 
Drug/biomarker associations in the profile include 
both on and off-label drugs for ovarian cancer. Thus, many 
patients received results for drugs outside of the National 
Comprehensive Cancer Network guidelines for treatment 
of EOC (on-compendium vs. off-compendium). 12% of 
patients in the Matched cohort (14/121) received an off-
compendium agent compared to 23% in the Unmatched 
cohort (24/103). The majority (68%) of off-compendium 
agents administered were not associated with a profile 
biomarker and were classified in the “neither” category 
(26/38). Few physicians used the profile results to 
prescribe off-compendium drugs predicted to be of benefit 
(only three patients in each arm).
Figure 3: The average number of drugs that were predicted to be of benefit (blue) or lack-of-benefit (red) for each 
cohort compared to the average number of drugs that the patients actually received (calculated from diagnosis). 
Table 2: Number and frequency of results for notable biomarkers

















Platinum ERCC1 176 143 33 133 (93.0%) 31 (93.9%)
Taxane
TUBB3 163 92 74 80 (87.0%) 63 (85.1%)
PGP 200 185 17 159 (79.5%) 14 (82.4%)
Gemcitabine RRM1 207 155 55 61 (39.4%) 11 (20.0%)
Liposomal 
doxorubicin TOP2A 182 124 63 42 (33.9%) 14 (22.2%)
Topotecan TOPO1 207 103 106 18 (17.5%) 18 (17.0%)




Patients in the Matched cohort experienced a 
significantly greater improvement in OS from the time 
of molecular profiling when compared to patients in the 
Unmatched cohort. Median OS from the time of tumor 
profiling for patients included in the Matched cohort 
was 36 months compared to 27 months for patients in 
the Unmatched cohort (HR 0.62, 95% CI 0.41-0.96; 
p < 0.03; Figure 4A). Patients who received more than 
one drug in the lack-of-benefit category trended towards 
worse OS than patients who received only a single drug 
in this category (data not shown). Median OS from the 
time of diagnosis for patients in the Matched cohort was 
80 months compared to 56 months for patients in the 
Unmatched cohort (HR 0.65, 95% CI 0.43-0.99; p=0.045). 
Notable biomarkers with demonstrable differences 
between the Matched and Unmatched cohorts include 
ERCC1, TUBB3, and PGP. Levels of the taxane-resistance 
markers PGP (HR 0.47, 95% CI 0.25-0.89, p=0.019) and 
TUBB3 (HR 0.51, 95% CI 0.30-0.87, p=0.012) were 
significantly different between the two cohorts (Figure 
4B and 4C). While not significant, patients with low 
ERCC1 by IHC had improved OS (HR 0.62, 95% CI 
0.36-1.06, p=0.08). Each of these markers shows a similar 
trend whereby patients with increased expression have 
worse OS relative to patients that do not overexpress the 
proteins. In addition, OS decreased for patients who had 
more than one of these discrepant biomarkers. Patients 
positive for either one or more than one of these markers 
had significantly lower OS than patients who were not 
positive for any of the markers (Figure 4D). 
DISCUSSION
This initial report evaluating molecularly profiled 
patients enrolled in an observational registry demonstrates 
improved OS in EOC patients treated with agents of 
Figure 4: Kaplan-Meier curves: A. Kaplan-Meier curve showing the increase in overall survival from time of profiling for those 
patients treated only with therapies predicted to be of benefit by their molecular profile compared to those patients who received at least one 
therapy predicted be lack-of-benefit (HR 0.62, p=0.0295). Kaplan-Meier curves for patients who were positive for TUBB3 (B) and PGP 
(C). D: Kaplan-Meier curves showing that patients with over-expression of multiple markers have decreased overall survival. The green 
line shows patients who were positive for two or more biomarkers from the set ERCC1, PGP, RRM1, and TUBB3. The red line shows 
patients who were positive for only one biomarker from this set. The black line shows patients who were not positive for any biomarkers 
in this set.
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potential benefit when compared to patients who received 
agents associated with lack-of-benefit. Further analysis of 
the biomarker-drug combinations revealed that patients 
in the Unmatched cohort were less likely to benefit from 
platinum and taxanes , therapies commonly given to EOC 
patients, both in front-line and recurrent settings. This 
suggests that these markers (ERCC1, TUBB3 and PGP) 
are prognostic and could be predictive; however, almost 
every woman in this study was treated with a platinum/
taxane combination therapy, thus confounding the 
predictive utility of the individual markers. 
Unsurprisingly, the vast majority of patients 
received platinum and taxanes regardless of whether the 
profile report predicted a benefit from the drug. While 
this would be expected no matter when in the course of 
the disease the profile report was received, most of these 
patients were profiled following the application of primary 
therapy. In contrast to platinums and taxanes, gemcitabine 
and doxorubicin were more likely to be given only when 
the profile report recommended benefit, suggesting 
that, once patients were in the platinum-resistant state, 
physicians were using the profile to direct salvage therapy. 
A minority of patients in each cohort received 
non-NCCN guideline agents, however, most of these 
drugs were of the “neither” category, indicating that 
the profile provided no predictive data for these agents. 
The Unmatched cohort received more off-compendium 
agents than the Matched cohort. Of the off-compendium 
agents that were associated with a profiled biomarker, 
the majority of agents were administered against the 
profile recommendation, suggesting that physicians were 
following the profile results less often as their patients’ 
diseases advanced (i.e., trying unconventional treatments 
in desperate patients regardless of molecular evidence). 
There were no clear trends in off-compendium agents 
administered. 
The Unmatched cohort received 1.2 more lines of 
therapy than the Matched cohort and experienced inferior 
OS. One explanation for this finding is that it is the result 
of inherent biologic selection of an intrinsically resistant 
phenotype, which would be expected to be resistant to 
multiple additional therapies. This is supported by the 
observation that the ratio of benefit to lack-of-benefit 
drugs in the Matched cohort was 2.01 while the ratio of 
benefit to lack-of-benefit drugs in the Unmatched cohort 
was 1.17. However, the survival curves from time of 
diagnosis initially overlap and then diverge after profiling 
occurs. This type of divergence would suggest that basing 
therapy on tumor profiling has an effect on selecting 
optimal therapies and improving OS. 
Independent biomarker analysis identified the 
phenotype of a particularly poor-performing subset of 
patients. This poor-performing phenotype was defined 
as having high levels of at least two markers in the set 
of ERCC1, PGP, RRM1, and TUBB3 (double-positive 
EOC). Our data identified 24% of patients as having this 
phenotype (of 86 cases who had all 4 markers tested), with 
a higher concentration in the Unmatched cohort (Matched 
10% and Unmatched 45%). We believe this group 
represents a previously unrecognized subtype of EOC 
patients who experience inferior OS when treated with 
the standard-of-care platinum/taxane combination and 
should be identified early for alternative treatments such 
as liposomal doxorubicin, topotecan, cyclophosphamide, 
bevacizumab or a clinical trial. We do not believe that 
this phenotype is simply a function of the profiling of 
previously treated, resistant tumors, as 72% of the double-
positive-or-higher arm (Figure 4D) were profiled using 
treatment-naïve samples (56% of the quadruple-negative 
arm samples were treatment-naïve). 
In any prospective observational study, there can 
be significant sources of bias that diminish the strength 
of the conclusions obtained from the data.  This study is 
no different, in that even though the cohorts were well 
balanced, there was no randomization to control for 
unknown sources of bias. Performing a randomized study 
in this population would be challenging as the required 
numbers for enrollment would be high and the follow-
up time for OS would be 5-10 years.  Additionally, there 
could be ethical concerns of randomizing patients to a non-
profiled arm, as many EOC patients receive some amount 
of profiling as part of their routine care. The data do allow 
for a number of potential sources of bias to be eliminated, 
specifically age, race, stage, histology, grade, and site of 
biopsy.  Other potential sources of bias include physicians 
self-selecting patients for the study by choosing to profile 
some patients versus others and physicians choosing to 
follow or not follow the biomarker recommendations 
based on unrecorded patient characteristics. The data also 
show heavy censoring early in the Kaplan-Meier curves 
for both patient cohorts, which reflects the nine-month 
minimum follow-up window and the immature clinical 
follow-up of this Registry. However, the median follow-up 
time was over a year, and median survival was reached for 
both cohorts, suggesting that the maturity of the Registry 
was sufficient for the analyses performed in this study.
In conclusion, this report suggests a potential 
predictive role of molecular profiling to avoid use of 
inactive therapies. Additionally, a prognostic biomarker-
derived phenotype was identified that demonstrated 
particularly inferior OS. The conclusions generated here, 
while intriguing, will need to be validated in an additional 





Molecular profiling was performed using 
a multiplatform approach (Caris Life Sciences® 
Molecular Intelligence™ [CMI™]) to stratify agents by 
degree of potential therapeutic benefit. Tumor biopsy 
samples were analyzed with a combination of Sanger 
sequencing, next generation sequencing, pyrosequencing, 
immunohistochemistry (IHC), gene amplification with 
fluorescent/chromogenic in-situ hybridization (F/C-ISH), 
and ribonucleic acid fragment analysis depending on 
physician request.  
IHC analysis was performed on formalin-fixed 
paraffin-embedded tumor samples using commercially 
available detection kits, automated staining techniques 
(Benchmark X, Ventana, AutostainerLink 48, Dako), 
and commercially available antibodies: ERCC1 (8F1, 
Abcam), RRM1 (10526-1-AP, Proteintech), PGP (C494, 
Invitrogen), TUBB3 (PRB-435P, BioLegend; see 
supplemental materials for full list of antibodies). 
FISH was used for evaluation of HER-2/neu [HER-
2/CEP17 probe], EGFR [EGFR/CEP7 probe], and cMET 
[cMET/CEP7 probe] (Abbott Molecular/Vysis). HER-2/
neu and cMET status were evaluated by CISH (INFORM 
HER-2 Dual ISH DNA Probe; commercially available 
cMET and chromosome 7 DIG probe; Ventana). The same 
scoring system was applied as for FISH.  
Direct sequence analysis was performed on genomic 
DNA isolated from formalin-fixed paraffin-embedded 
tumor samples using the Illumina MiSeq platform. 
Specific regions of 45 genes of the genome were amplified 
using the Illumina TruSeq Amplicon Cancer Hotspot 
panel.  Mutation analysis by Sanger sequencing included 
selected regions of BRAF, KRAS, c-KIT, EGFR, and 
PIK3CA genes and was performed by using M13-linked 
PCR primers designed to amplify targeted sequences.
Statistical considerations
The Caris Registry (NCT02678754)  was queried for 
all patients with a diagnosis of ovarian, primary peritoneal 
and fallopian tube carcinomas enrolled between 2010 
and 2014. This IRB-approved prospective observational 
study includes baseline clinical information at the time 
of profiling (not necessarily at the time the pathologic 
material was obtained), profiling results, treatments 
received and clinical outcomes, including PFS and OS, 
updated at nine-month intervals after enrollment (as 
specified in the Registry protocol). Survival was calculated 
from the date of molecular profiling and from the date of 
diagnosis to the date of death or last follow-up date. OS 
from the date of molecular profiling was chosen as the 
primary endpoint.
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